Treatment options and patient perspectives in the management of fibromyalgia: future trends

Kim LawsonBiomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, Sheffield, UKAbstract: Fibromyalgia (FM) is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological a...

Full description

Bibliographic Details
Main Author: Kim Lawson
Format: Article
Language:English
Published: Dove Medical Press 2008-11-01
Series:Neuropsychiatric Disease and Treatment
Online Access:http://www.dovepress.com/treatment-options-and-patient-perspectives-in-the-management-of-fibrom-a2577
id doaj-1ebe2bb6c362452188fdf89c5b8268a5
record_format Article
spelling doaj-1ebe2bb6c362452188fdf89c5b8268a52020-11-24T23:09:02ZengDove Medical PressNeuropsychiatric Disease and Treatment1176-63281178-20212008-11-012008Issue 610591071Treatment options and patient perspectives in the management of fibromyalgia: future trendsKim LawsonKim LawsonBiomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, Sheffield, UKAbstract: Fibromyalgia (FM) is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological and non-pharmacological (education and exercise) interventions. It is a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, sleep dysfunction, and fatigue, where the pathophysiology could include dysfunction of the central nervous system pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. A cyclic model of the pathophysiological processes is compatible with the interrelationship of primary symptoms and the array of postulated triggers associated with FM. Many of the molecular targets of current and emerging drugs used to treat FM have been focused to the management of discrete symptoms rather than the condition. Recently, drugs (eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have been identified that demonstrate a multidimensional efficacy in this condition. Although the complexity of FM suggests that monotherapy, non-pharmacological or pharmacological, will not adequately address the condition, the outcomes from recent clinical trials are providing important clues for treatment guidelines, improved diagnosis, and condition-focused therapies.Keywords: fibromyalgia, pain, sleep dysfunction, fatigue, exercise, pharmacological treatments http://www.dovepress.com/treatment-options-and-patient-perspectives-in-the-management-of-fibrom-a2577
collection DOAJ
language English
format Article
sources DOAJ
author Kim Lawson
spellingShingle Kim Lawson
Treatment options and patient perspectives in the management of fibromyalgia: future trends
Neuropsychiatric Disease and Treatment
author_facet Kim Lawson
author_sort Kim Lawson
title Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_short Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_full Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_fullStr Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_full_unstemmed Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_sort treatment options and patient perspectives in the management of fibromyalgia: future trends
publisher Dove Medical Press
series Neuropsychiatric Disease and Treatment
issn 1176-6328
1178-2021
publishDate 2008-11-01
description Kim LawsonBiomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, Sheffield, UKAbstract: Fibromyalgia (FM) is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological and non-pharmacological (education and exercise) interventions. It is a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, sleep dysfunction, and fatigue, where the pathophysiology could include dysfunction of the central nervous system pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. A cyclic model of the pathophysiological processes is compatible with the interrelationship of primary symptoms and the array of postulated triggers associated with FM. Many of the molecular targets of current and emerging drugs used to treat FM have been focused to the management of discrete symptoms rather than the condition. Recently, drugs (eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have been identified that demonstrate a multidimensional efficacy in this condition. Although the complexity of FM suggests that monotherapy, non-pharmacological or pharmacological, will not adequately address the condition, the outcomes from recent clinical trials are providing important clues for treatment guidelines, improved diagnosis, and condition-focused therapies.Keywords: fibromyalgia, pain, sleep dysfunction, fatigue, exercise, pharmacological treatments
url http://www.dovepress.com/treatment-options-and-patient-perspectives-in-the-management-of-fibrom-a2577
work_keys_str_mv AT kimlawson treatmentoptionsandpatientperspectivesinthemanagementoffibromyalgiafuturetrends
_version_ 1725611864087330816